Triptorelln Acetate

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

I. Core Structure & Key Traits

1. Molecular Composition
   
   
   Triptorelin Acetate has the amino acid sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂, with a pyroglutamic acid residue at the N-terminus and an amidated glycine at the C-terminus. The substitution of L-tryptophan with D-tryptophan at position 6 significantly enhances its resistance to enzymatic degradation and receptor binding affinity, extending its in vivo half-life compared to endogenous GnRH.
2. Formulation & Storage
   
   
   It is commercially available as sterile lyophilized powder for injection, suitable for subcutaneous or intramuscular administration. Long-acting depot formulations (e.g., microsphere-encapsulated preparations) are also available, enabling once-monthly dosing. Store the lyophilized powder at 2–8°C away from light; avoid repeated freeze-thaw cycles. Reconstitute with sterile water or normal saline before use, and the prepared solution should be administered immediately.

II. Mechanism of Action

1. Initial Stimulatory Phase
   
   
   In the first 1–2 weeks of administration, it binds to GnRH receptors to stimulate the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing serum levels of testosterone (in males) and estrogen (in females).
2. Sustained Desensitization Phase
   
   
   Prolonged exposure to the agonist causes downregulation and desensitization of pituitary GnRH receptors, leading to a significant reduction in LH and FSH secretion. This subsequently suppresses gonadal steroid hormone synthesis, achieving a state of "medical castration" which is the basis for its therapeutic applications.

III. Clinical Applications & Research Value

1. Hormone-Dependent Cancers
   • Prostate Cancer: First-line treatment for advanced prostate cancer; reduces testosterone levels to castration-resistant levels, inhibiting tumor growth.
   • Breast Cancer: Used for the treatment of estrogen receptor-positive metastatic breast cancer in premenopausal women.
   • Gynecological Malignancies: Indicated for endometrial cancer and ovarian cancer that are sensitive to hormone suppression.
   
   
2. Benign Gynecological Disorders
   • Endometriosis: Relieves pelvic pain, dysmenorrhea, and reduces endometrial lesion size by suppressing estrogen production.
   • Uterine Fibroids: Shrink fibroid volume and reduce abnormal uterine bleeding, serving as a preoperative preparation to minimize surgical trauma.
   
   
3. Reproductive Medicine
   • Assisted Reproductive Technology (ART): Used for ovarian hyperstimulation protocols to regulate follicular development and control the timing of ovulation.
   • Central Precocious Puberty: Inhibits the premature activation of the hypothalamic-pituitary-gonadal axis, delaying the progression of puberty and improving final adult height in affected children.
   
   
4. Research Applications
   
   
   Serves as a tool in endocrinology research to study the hypothalamic-pituitary-gonadal axis function and to develop novel GnRH analogs with improved pharmacokinetic properties.

IV. Dosage, Administration & Safety Profile

1. Recommended Dosage
   • Advanced Prostate Cancer: 3.75 mg intramuscular injection once every 4 weeks (long-acting depot formulation); or 0.1 mg subcutaneous injection daily.
   • Endometriosis/Uterine Fibroids: 3.75 mg intramuscular injection once every 4 weeks for 3–6 months.
   • Central Precocious Puberty: Dose adjusted by body weight, typically 0.1–0.3 mg subcutaneous injection once every 4 weeks.
   
   
2. Adverse Reactions
   • Initial Flare Reaction: Transient increase in tumor-related symptoms (e.g., bone pain in prostate cancer) or menstrual irregularities in the first week of treatment, which can be mitigated by concurrent use of antiandrogens/antiestrogens.
   • Hypogonadism-Related Symptoms: Hot flashes, decreased libido, erectile dysfunction, vaginal dryness, and bone loss (long-term use may require calcium and vitamin D supplementation).
   • Other Mild Reactions: Injection-site pain, headache, fatigue, and gastrointestinal disturbances, which are mostly self-limiting.
   
   
3. Contraindications & Precautions
   
   
   Contraindicated in pregnant or lactating women, individuals with hypersensitivity to triptorelin or its excipients, and patients with untreated hormone-independent tumors. Use with caution in patients with osteoporosis, cardiovascular diseases, or liver/kidney dysfunction.